The world's first mRNA vaccine against a deadly disease

Published Date: 15 Mar 2023

A world first: A research team from Tel Aviv University and the Israel Institute of Biology has developed an anti-mRNA drug that is 100% effective against a single type of virus.

Read Full News

Latest News

A Cracked Coffin, a Funeral and the Hunt for Ebola's Patient Zero

By the time the truck pulled away from the morgue in Bunia, the morning heat hung heavily over the road to Mongbwalu.

Two Babies From Congo Orphanage Die Of Ebola, Highlighting Risk to Children

After her mother died in late May, baby Buswaza was brought to a church-run orphanage in eastern Congo where the nuns quickly discovered the newborn was running a...

The Cost of Complacency: Measles on the Rise in Canada

The current outbreak has demonstrated the effectiveness of vaccination, and physicians play a crucial role in rebuilding confidence in vaccines.

C difficile Hospital Deaths Rose in the COVID Pandemic

Clostridioides difficile infection, especially complicated by COVID, elevates nosocomial mortality risk in the US, whereas admissions decrease.

Deep Dive: When Hitting the LDL Target Isn't Enough

The case for lowering LDL-C is strong. It is not, however, the whole story.

US Doctor Isolated in Czech Hospital for Ebola Monitoring Released, Heading Home

A U.S. doctor who was transferred to a Czech hospital from ⁠Uganda last month as a precaution after having contact with a patient with ⁠Ebola has been released and is on his...

Todays Updates

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Todays Updates

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Latest News

By the time the truck pulled away from the morgue in Bunia, the morning heat hung heavily over the road to Mongbwalu.

After her mother died in late May, baby Buswaza was brought to a church-run orphanage in eastern Congo where the nuns quickly discovered the newborn was running a...

The current outbreak has demonstrated the effectiveness of vaccination, and physicians play a crucial role in rebuilding confidence in vaccines.

Clostridioides difficile infection, especially complicated by COVID, elevates nosocomial mortality risk in the US, whereas admissions decrease.

The case for lowering LDL-C is strong. It is not, however, the whole story.

A U.S. doctor who was transferred to a Czech hospital from ⁠Uganda last month as a precaution after having contact with a patient with ⁠Ebola has been released and is on his...

News All Time

Lyme Primer: How the HHS Strategy Stacks Up To Science

Experts support targeting ticks but caution against the long-term use of antibiotics.

TNFi Use in Early Peripheral SpA Outperforms Methotrexate

‘These data [from the phase 3 SPARTACUS trial] support the importance of early diagnosis and early treatment before structural damage,’ said one expert not involved in the research.

FDA Approves First New Sunscreen Option in Two Decades

Bemotrizinol protects against both ultraviolet A and B rays, has low absorption through the skin, and is safe for adults and children 6 months and older, according to the FDA.

US Adds $38 Million for Ebola as CDC Warns Outbreak Could Match 2014

The United States said on Friday it would provide an additional $38 million for Ebola response efforts, as the CDC warned that without strong public health interventions the...

New POCUS for Residents: Should Hospitalists Join?

Few attending hospitalists have formal training in point-of-care ultrasound, but more are eager to learn.

Hospitalists Leading Health Informatics in the Digital Age

Technology in hospitals is changing quickly, having clinicians at the helm makes a difference.

Whole Blood vs Components: No Survival Benefit in Trauma

Prehospital transfusion with whole blood was not linked to reduced 30-day mortality compared with prehospital transfusion with blood components in patients with traumatic hemorrhage, a phase 3 trial finds.

'They're Betting Our Herd': Texas Ranchers Question USDA as Screwworm Returns

Like many ranchers in South Texas, Susan Storey said nightmarish screwworm outbreaks were among her first childhood memories. Now 62, she still recalls seeing wriggling...

Health Experts to Screen US Wastewater for Disease Outbreaks During World Cup

Epidemiologists will be busy this summer sifting through sewage and social media with the goal of keeping soccer fans and the public safe from severe illness during the...

Mental Health System Failing Women, Psychiatrists Warn

A Royal College of Psychiatrists strategy highlights how women's mental health needs are often overlooked, despite higher rates of common mental disorders.

Oral Glucocorticoids Linked to Higher Candidemia Risk

The use of oral glucocorticoids increases the odds of developing candidemia in a dose-dependent fashion; effects are strongest in users with inflammatory bowel disease.

Australian Cancer Specialist Richard Scolyer Dies At 59 After Pioneering Treatment

Richard Scolyer, the Australian cancer specialist who became a test case for an experimental treatment after being diagnosed with ⁠an aggressive brain tumour, has died aged...

SARS-CoV-2 Poses Greater Autoimmune Risk Than Vaccines

Spanish dermatologists report that vaccine-related skin eruptions are uncommon, while SARS-CoV-2 infection itself is more strongly linked to autoimmune and vascular complications.

When Your Loved Ones Trust TikTok Over Their Doctor — & You

Physicians recount how health disinformation damaged close relationships and forced them to rethink how to advise loved ones.

COVID Was Just the Start: What’s Next for mRNA?

Advances in mRNA design and delivery support new therapies for cancer, rare diseases, and chronic conditions, extending the platform far beyond infectious diseases.

Bimekizumab Trumps Risankizumab in Head-to-Head PsA Trial

Dual IL-17A/F inhibition was superior to IL-23 inhibition for managing joint involvement in psoriatic arthritis, according to findings from the phase 3b BE BOLD study.